Non-tuberculous Mycobacteria

Department of Health and Social Care written question – answered on 14th June 2022.

Alert me about debates like this

Photo of Baroness Masham of Ilton Baroness Masham of Ilton Crossbench

To ask Her Majesty's Government what assessment they have made of the impact on patients with non-tuberculous mycobacteria should there be a delay to the next meeting of the NHS England's Clinical Priorities Advisory Group.

Photo of Baroness Masham of Ilton Baroness Masham of Ilton Crossbench

To ask Her Majesty's Government what measures are in place to test patients treated with macrolide therapy for non-tuberculous mycobacteria; and how many of these tests have been undertaken in England.

Photo of Lord Kamall Lord Kamall The Parliamentary Under-Secretary for Health and Social Care

No formal assessment has been made. Patients with non-tuberculous mycobacteria will continue to be managed in primary and secondary care settings and treated with the current available treatments known as ‘Guideline Based Therapy’ as recommended by the British Thoracic Society.

The British Thoracic Society guideline for the use of longterm macrolides in adults with respiratory disease suggests that patients who are able to expectorate should be considered for testing for non-tuberculous mycobacteria prior to starting long-term macrolide therapy. A copy of the guideline is attached. NHS England and NHS Improvement do not hold data on the number of tests undertaken.

Guideline for Long Term Macrolide Use (pdf, 1051.5KB)

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.